Supply and Clinical Application of Actinium-225 and Bismuth-213

The recent development of (225)Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters (225)Actinium and its daughter nuclide (213)Bismuth include the therapy of brain tumors, bladder...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgenstern, Alfred, Apostolidis, Christos, Bruchertseifer, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082773/
https://www.ncbi.nlm.nih.gov/pubmed/32172796
http://dx.doi.org/10.1053/j.semnuclmed.2020.02.003
_version_ 1783508412674342912
author Morgenstern, Alfred
Apostolidis, Christos
Bruchertseifer, Frank
author_facet Morgenstern, Alfred
Apostolidis, Christos
Bruchertseifer, Frank
author_sort Morgenstern, Alfred
collection PubMed
description The recent development of (225)Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters (225)Actinium and its daughter nuclide (213)Bismuth include the therapy of brain tumors, bladder cancer, neuroendocrine tumors, and leukemia. This paper will provide a brief overview on the current status of the clinical development of compounds labelled with (225)Ac or (213)Bi and describe the various production routes that are in place or are under development to meet the increasing demand for these radionuclides.
format Online
Article
Text
id pubmed-7082773
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher W.B. Saunders
record_format MEDLINE/PubMed
spelling pubmed-70827732020-03-24 Supply and Clinical Application of Actinium-225 and Bismuth-213 Morgenstern, Alfred Apostolidis, Christos Bruchertseifer, Frank Semin Nucl Med Article The recent development of (225)Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters (225)Actinium and its daughter nuclide (213)Bismuth include the therapy of brain tumors, bladder cancer, neuroendocrine tumors, and leukemia. This paper will provide a brief overview on the current status of the clinical development of compounds labelled with (225)Ac or (213)Bi and describe the various production routes that are in place or are under development to meet the increasing demand for these radionuclides. W.B. Saunders 2020-03 /pmc/articles/PMC7082773/ /pubmed/32172796 http://dx.doi.org/10.1053/j.semnuclmed.2020.02.003 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Morgenstern, Alfred
Apostolidis, Christos
Bruchertseifer, Frank
Supply and Clinical Application of Actinium-225 and Bismuth-213
title Supply and Clinical Application of Actinium-225 and Bismuth-213
title_full Supply and Clinical Application of Actinium-225 and Bismuth-213
title_fullStr Supply and Clinical Application of Actinium-225 and Bismuth-213
title_full_unstemmed Supply and Clinical Application of Actinium-225 and Bismuth-213
title_short Supply and Clinical Application of Actinium-225 and Bismuth-213
title_sort supply and clinical application of actinium-225 and bismuth-213
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082773/
https://www.ncbi.nlm.nih.gov/pubmed/32172796
http://dx.doi.org/10.1053/j.semnuclmed.2020.02.003
work_keys_str_mv AT morgensternalfred supplyandclinicalapplicationofactinium225andbismuth213
AT apostolidischristos supplyandclinicalapplicationofactinium225andbismuth213
AT bruchertseiferfrank supplyandclinicalapplicationofactinium225andbismuth213

Ejemplares similares